By: Editorial Staff
Date: May 08, 2026
On World Ovarian Cancer Day, the medical community and patient advocacy groups pause to acknowledge the silent, often devastating impact of a disease that frequently escapes early detection. Among those standing at the front lines of this battle is Susan Peluso, whose personal journey serves as a poignant reminder of both the fragility of life and the resilience of the human spirit. Her narrative, shared on this day of global awareness, offers a stark look at the reality of stage 4B high-grade serous ovarian cancer and the vital importance of self-advocacy.
The Invisible Thief: An Overview of the Diagnosis
For many, the diagnosis of ovarian cancer is a seismic event that splits life into two distinct eras: the "before" and the "after." For Susan Peluso, that shift occurred in March 2023. At 54 years old, Peluso considered herself a healthy, active individual. There were no warning signs that would typically trigger alarm bells, save for a sharp, localized rectal pain.
Initially dismissed as mere spasms, the symptom was a red herring that masked a much more sinister reality. When the medical diagnosis finally arrived—high-grade serous ovarian cancer—it was already advanced. This scenario is, unfortunately, common in the oncology world. Ovarian cancer is notoriously difficult to detect in its early stages. Because the ovaries are tucked deep within the pelvic cavity, symptoms are often vague—bloating, pelvic pain, or digestive discomfort—which frequently leads patients and their primary care physicians to look for more benign causes first.
A Chronology of Resilience: The Medical Timeline
To understand the burden of this diagnosis, one must look at the grueling timeline of treatment that followed Peluso’s initial discovery.
The Initial Onslaught (2023)
- March 2023: Diagnosis of stage 4B high-grade serous ovarian cancer.
- May 2023: A major surgical intervention involving a complete hysterectomy and comprehensive debulking surgery. At this stage, the cancer had already disseminated to multiple organs, underscoring the aggressive nature of the disease.
- Summer 2023: Following recovery from surgery, Peluso commenced a rigorous six-round chemotherapy regimen.
The Maintenance Phase and NED (2023–2025)
- October 2023 – February 2025: Peluso underwent 21 cycles of Avastin (bevacizumab), a targeted therapy designed to starve tumors of their blood supply.
- The "NED" Period: For 26 months post-chemotherapy and one year past her final Avastin treatment, Peluso achieved "No Evidence of Disease" (NED). This phase is often described by patients as a "fragile, beautiful space," where the immediate shadow of active treatment retreats, allowing for a semblance of normalcy.
The Recurrence and The Current Battle (2026)
- January 2026: Hope was momentarily shaken when follow-up scans revealed a recurrence. A CT scan and liver MRI confirmed the return of the disease.
- March 2, 2026: Peluso underwent a second debulking surgery, demonstrating the surgical persistence required to manage recurrent ovarian cancer.
- April 8, 2026: The commencement of a new cycle of chemotherapy.
The Clinical Reality: Why Early Detection Remains Elusive
The statistics surrounding ovarian cancer are sobering. According to data from the American Cancer Society and global oncology registries, ovarian cancer ranks as the fifth leading cause of cancer-related death among women. The primary challenge remains the lack of a standardized, reliable screening test for the general population.
Unlike breast cancer, which has mammography, or cervical cancer, which has the Pap smear and HPV testing, ovarian cancer lacks a "gold standard" early detection tool. This leads to the majority of cases being diagnosed at Stage III or IV, where the cancer has already spread beyond the ovaries.
The Importance of Symptom Awareness
Medical experts emphasize the "Rule of Three" for ovarian symptoms: if symptoms such as abdominal bloating, pelvic or abdominal pain, and difficulty eating or feeling full quickly occur consistently for more than three weeks, medical investigation is imperative. However, as Peluso’s case illustrates, even symptoms that seem unrelated to the reproductive system—such as the rectal pain she experienced—must be investigated thoroughly if they persist.
Supporting the Patient: The Role of Advocacy Groups
The physical toll of cancer is only half the battle; the psychological and emotional burden is equally heavy. Organizations like Sharsheret, which provides support for women facing breast and ovarian cancer, play a critical role in the continuum of care.
For patients like Peluso, these organizations serve as a lifeline. They provide more than just information; they offer a community of individuals who understand the nuances of the "before and after" divide. By fostering a sense of identity beyond the diagnosis, these groups empower patients to take an active role in their care.
"What carries me through is not just treatment, but the people and organizations like Sharsheret who lift me up and remind me who I am beyond this diagnosis," Peluso notes. This sentiment highlights the "whole-person" approach required in modern oncology. Patients are not merely a collection of symptoms or scan results; they are individuals navigating the complexities of survivorship, recurrence, and the persistent desire for a future.
Implications for the Future
The story of Susan Peluso is a call to action for both patients and the medical establishment.
For Patients
The message is clear: Listen to your body. Peluso’s journey underscores the necessity of self-advocacy. If a diagnosis does not seem to fit the symptoms, or if symptoms persist despite initial treatment, patients must feel empowered to seek second opinions and request more advanced imaging or specialized consultations.
For the Medical Community
The persistence of late-stage diagnoses highlights a desperate need for innovation in biomarker research and liquid biopsies. While surgical techniques and systemic therapies (like targeted maintenance treatments) have extended survival rates significantly, the ultimate goal remains moving the diagnostic needle from Stage IV to Stage I.
The Societal Perspective
World Ovarian Cancer Day is not merely a day for ribbons; it is a day for education. When patients like Peluso share their stories, they demystify the disease and strip away the stigma that can often accompany a cancer diagnosis. By speaking openly about her second surgery and the restart of chemotherapy, Peluso provides a roadmap for others: one of radical honesty and unwavering hope.
Conclusion: A Testament to Resilience
As of May 2026, Peluso remains in the midst of her second round of active treatment. She acknowledges that this is not the chapter she wanted to write, yet she continues to live it with a profound sense of purpose.
Her message is one that resonates far beyond the clinical walls of the oncology ward. It is a reminder that while medical science strives for cures, the human capacity to fight, to hope, and to advocate remains the most powerful tool in the arsenal. On this World Ovarian Cancer Day, her testimony stands as a beacon for others: to remain vigilant, to remain supported, and, above all, to remain hopeful.
If you or a loved one are concerned about symptoms or have been recently diagnosed with ovarian cancer, contact organizations such as Sharsheret or the Ovarian Cancer Research Alliance (OCRA) for guidance, support, and resources.
About the Author
